Cited by 169Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeuroscience and Neuropharmacology Research

Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies

Open access
Ji, Bin, Maeda, Jun, Sawada, Makoto, Ono, Maiko, Okauchi, Takashi, Inaji, Motoki, Zhang, Ming-Rong, Suzuki, Kazutoshi +6 more·2008·The Journal of Neuroscience

Abstract

We demonstrate the significance of peripheral benzodiazepine receptor (PBR) imaging in living mouse models of Alzheimer's disease (AD) as biomarkers and functional signatures of glial activation. By radiochemically and immunohistochemically analyzing murine models of the two pathological hallmarks of AD, we found that AD-like Aβ deposition is concurrent with astrocyte-dominant PBR expression, in striking contrast with nonastroglial PBR upregulation in accumulations of AD-like phosphorylated tau. Because tau-induced massive neuronal loss was distinct from the marginal neurodegeneration associated with Aβ plaques in these models, cellular localization of PBR reflected deleterious and beneficial glial reactions to tau versus Aβ pathologies, respectively. This notion was subsequently examined in models of various non-AD neuropathologies, revealing the following reactive glial dynamics underlying differential PBR upregulation: (1) PBR(−) astrogliosis uncoupled with microgliosis or coupled with PBR(+) microgliosis associated with irreversible neuronal insults; and (2) PBR(+) astrogliosis coupled with PBR(− or ±) microgliosis associated with minimal or reversible neuronal toxicity. Intracranial transplantation of microglia also indicated that nontoxic microglia drives astroglial PBR expression. Moreover, levels of glial cell line-derived neurotrophic factor (GDNF) in astrocytes were correlated with astroglial PBR, except for increased GDNF in PBR(-) astrocytes in the model of AD-like tau pathology, thereby suggesting that PBR upregulation in astrocytes is an indicator of neurotrophic support. Together, PBR expressions in astrocytes and microglia reflect beneficial and deleterious glial reactions, respectively, in diverse neurodegenerative disorders including AD, pointing to new applications of PBR imaging for monitoring the impact of gliosis on the pathogenesis and treatment of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2312-08.2008

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In models of Alzheimer's-like neurodegeneration, TSPO positive microglia, astrocytes and endothelium are all increased.

    “Similarly, others have found that TSPO positive microglia, astrocytes and endothelium are all increased in models of Alzheimer’s-like neurodegeneration [48–51] and in postmortem human Alzheimer’s disease brains [27].”

    From Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease (2023) · cites this paper as [48]

    The Results section, “Distinct cellular localizations of PBR in models of Aβ and tau pathologies” (page unavailable), reports PBR-positive astrocytes near plaques in APP23 mice and PBR-positive microglia in PS19 tau mice. It does not report increased PBR-positive endothelium. It also distinguishes the two models rather than finding that all three cell types increased in each. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 71 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., Trojanowski, J. Q., Lee, V. M. Y., Higuchi, M., & Suhara, T.
Affiliations
  • National Institute of Radiological Sciences (JP)
  • Research Institute of Environmental Medicine, Nagoya University (JP)
  • Central Institute for Experimental Animals (JP)
  • Novartis (Switzerland) (CH)
  • University of Pennsylvania (US)
Corresponding author
Higuchi, Makoto
Venue
The Journal of Neuroscience
Published
2008-11-19
Volume
28
Issue
47
Pages
12255-12267
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2030029215
Cited by
169
References
71
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 7 · 2021: 16 · 2020: 13 · 2019: 4 · 2018: 10 · 2017: 12 · 2016: 14 · 2015: 14 · 2014: 12 · 2013: 9 · 2012: 10
FWCI
7.02
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
  • QST-Repository (National Institutes for Quantum and Radiological Science and Technology) (submittedVersion)
Funders
  • Japan Society for the Promotion of Science (20023036)
  • National Institute on Aging (P30AG010124)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
translocator protein (TSPO), Alzheimer's disease, glial activation, astrocyte activation, microglial activation, amyloid plaques, tau pathology, neurodegeneration, glial cell line-derived neurotrophic factor, neurotrophic support, neuroinflammation, neuroimaging biomarkers, mouse model
MeSH terms
Acetamides, Alzheimer Disease, Analysis of Variance, Animals, Cell Line, Transformed, Central Nervous System, Disease Models, Animal, Gene Expression Regulation, Glial Fibrillary Acidic Protein, Kainic Acid, Male, Mice, Inbred C57BL, Mice, Transgenic, Phenyl Ethers, Receptors, GABA-A, Amyloid beta-Protein Precursor, Oxidopamine, tau Proteins, Microglia, Cell Transplantation, Radiopharmaceuticals, Neurotoxicity Syndromes, Positron-Emission Tomography, Glial Cell Line-Derived Neurotrophic Factor, Mice, Rats, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review